Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | STK4 | Q13043 | 1/20 | 0.48 |
| ▸ | STK3 | Q13188 | 1/20 | 0.48 |
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216515 | 0.86 | CNR2 (0.58) | CNR2ATRATRIPCYP1A2LMNA | |
| SCHEMBL6633751 | 0.86 | CYP1A2 (0.57) | TACR1CYP1A2LMNACYP3A4HIF1A | |
| SCHEMBL4374064 | 0.85 | CYP1A2 (0.41) | CNR2TACR1CYP1A2CYP3A4MEN1 | |
| SCHEMBL7111358 | 0.84 | TACR1 (0.52) | CNR2TACR1STK4STK3CYP1A2 | |
| SCHEMBL4672501 | 0.83 | TACR1 (0.55) | CNR2TACR1STK4STK3CYP1A2 | |
| SCHEMBL4672437 | 0.82 | STK4 (0.47) | CNR2STK4STK3CYP1A2LMNA | |
| SCHEMBL4675475 | 0.82 | CNR2 (0.53) | CNR2TACR1STK4STK3ATR | |
| SCHEMBL12097112 | 0.81 | SMO (0.56) | TACR1CYP1A2LMNAHSD17B10CYP2D6 | |
| SCHEMBL905379 | 0.80 | CYP1A2 (0.54) | CNR2TACR1STK4STK3CYP1A2 | |
| SCHEMBL7144524 | 0.80 | CNR2 (0.51) | CNR2TACR1STK4STK3ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303490-B1 | N-OXIDES AS NK1 RECEPTOR ANTAGONIST PRODRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| EP-1309559-B1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2006-06-07 | — | — | EP | disclosed |
| EP-1305319-B1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2006-04-05 | — | — | EP | disclosed |
| US-6897226-B2 | NK-1 receptor active amine oxide prodrugs | HOFFMANN-LA ROCHE INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-6806370-B2 | NEUROKININ-1 RECEPTOR ANTAGONISTS ARE FURTHER USEFUL FOR THE TREATMENT OF MOTION SICKNESS AND FOR TREATMENT INDUCED VOMITING | HOFFMANN-LA ROCHE INC. | 2004-10-19 | — | — | US | disclosed |
| EP-1035115-B1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2004-09-29 | — | — | EP | disclosed |
| US-6770637-B2 | N-(3,5-BIS-TRIFLUOROMETHYL-BENZYL)-6-(4-HYDROXYACETYL-PIPERAZIN-1 -YL)-N-METHYL-4-O-TOLYL-NICOTINAMIDE, FOR EXAMPLE | HOFFMANN-LA ROCHE INC. | 2004-08-03 | — | — | US | disclosed |
| US-6747026-B2 | FOR THERAPY OF DISEASE RESPONSIVE TO ANTAGONIST MODULATION OF THE NEUROKININ-1 (NK-1) RECEPTOR IN A PATIENT | HOFFMAN-LA ROCHE INC. | 2004-06-08 | — | — | US | disclosed |
| US-20040048901-A1 | NK-1 receptor active amine oxide prodrugs | HOFFMANN TORSTEN (DE) | 2004-03-11 | — | — | US | disclosed |
| EP-1394150-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-20020040040-A1 | Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors | F. HOFFMAN-LA ROCHE AG (CH) | 2002-04-04 | — | — | US | disclosed |
| US-20020038030-A1 | Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-03-28 | — | — | US | disclosed |
| WO-2002016324-A1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002008232-A1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-31 | — | — | WO | disclosed |
| WO-2002006236-A1 | N-OXIDES AS NK1 RECEPTOR ANTAGONIST PRODRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
| US-6303790-B1 | REACTING SUBSTITUTED NICOTINAMIDE WITH GRIGNARD REAGENT, OXIDIZING PRODUCT, REACTING WITH HALO-SUBSTITUTED AROMATIC COMPOUND | HOFFMAN-LA ROCHE INC. | 2001-10-16 | — | — | US | disclosed |
| US-6297375-B1 | 4-phenyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1103545-A1 | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-30 | — | — | EP | disclosed |
| EP-1103546-A1 | Process for preparation of pyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-30 | — | — | EP | disclosed |
| EP-1035115-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040040-A1 | Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors | NPSR1, NTSR1, NTSR2 | CNR2 136/4885TACR1 4/4885STK4 1406/4885 |
| US-20040048901-A1 | NK-1 receptor active amine oxide prodrugs | TACR1, BDKRB1, NPSR1 | CNR2 344/4885TACR1 1/4885STK4 1704/4885 |
| US-20020038030-A1 | Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors | TACR1, NPSR1, TACR2 | CNR2 66/4885TACR1 1/4885STK4 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.